Clinical trials: Hepatitis C Virus (HCV)
Chronic Hepatitis C, Asian Americans
Pegasys and Copegus for Asian Patients With Treatment-naive Hepatitis C Genotypes 6, 7, 8, 9
The purpose of this research study is to test the safety, tolerability, and effectiveness of the drugs Pegasys and Copegus when used for hepatitis C genotypes 6, 7, 8, and 9.
- Conditions
- Chronic Hepatitis C, Asian Americans, Novel Genotypes, Treatment
- Trial name
- NCT00575224
- Testing
- Pegylated interferon and ribavirin
- Where
- 5 sites in United States
- Volunteers
- 60 people
- Sponsor
- Pacific Health Foundation
Hepatitis C, HIV
A Drug-drug Interaction Study Between Daclatasvir and Atazanavir/Ritonavir or Atazanavir/Cobicistat
This study aims to provide the evidence that 150mg of cobicistat will have the same effect on the pharmacokinetics of daclatasvir 30mg QD as 100mg of ritonavir, when given together with atazanavir 300mg.
- Trial name
- DATE-4 (NCT02565888)
- Testing
- Daclatasvir, Atazanavir, Ritonavir
- Where
- Netherlands
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
Chronic Hepatitis C
Study Assessing Single and Multiple Doses of IDX21459 in Healthy and HCV-Infected Subjects
A multi-part study to evaluate the safety and PK of single ascending doses of IDX21549 in healthy and HCV-infected subjects. The effect of food on the PK of IDX21549 will also be evaluated.
- Trial name
- NCT02112942
- Testing
- IDX21459
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C, Diabetes Mellitus
A Drug-drug Interaction Study Between Daclatasvir and Metformin
This study aims to provide clinical information on a potential drug-drug interaction between daclatasvir and metformin.
- Conditions
- Hepatitis C, Diabetes Mellitus, Insulin Resistance
- Trial name
- DATE-3 (NCT02565862)
- Testing
- Daclatasvir, Metformin
- Where
- Netherlands
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
Hepatitis C
Study of High Dosage CIFN Plus RBV for HCV Genotype 1 Infected Patients Who Are Nonresponders to Prior Therapy
The main purpose of this study is to evaluate the safety and tolerability of combination therapy of daily interferon alfacon-1 (Infergen, CIFN) at high dosage (24 mcg) with ribavirin (based on body weight) for 48 weeks in HCV…
- Trial name
- NCT00266318
- Testing
- Interferon Alfacon-1 and Ribavirin
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Beth Israel Medical Center
Hepatitis C
A Study of TMC435 in Combination With PSI-7977 (GS7977) in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive Patients
The purpose of this study is to investigate the efficacy and safety of TMC435 plus PSI-7977 (GS7977) with or without ribavirin in patients who are chronically infected with genotype 1 hepatitis C virus (HCV) and who did not…
- Trial name
- COSMOS (NCT01466790)
- Testing
- TMC435, PSI-7977 (GS7977), Ribavirin
- Where
- 23 sites in United States, Puerto Rico
- Volunteers
- 168 people
- Sponsor
- Janssen R&D Ireland
Hepatitis C, HIV Coinfection
Effects of Ledipasvir/Sofosbuvir on the Pharmacokinetics and Renal Safety of Tenofovir Alafenamide (TAF)
This study will evaluate the effect of ledipasvir/sofosbuvir (LDV/SOF) treatment on the pharmacokinetics (PK) and renal safety of tenofovir in the form of tenofovir alafenamide (TAF).
- Trial name
- NCT03126370
- Testing
- TDF with a boosted protease inhibitor, TAF with a boosted protease inhibitor, TAF with a boosted protease inhibitor and LDV/SOF
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Colorado, Denver
Chronic Hepatitis C
A Study to Evaluate the Safety, Tolerability, and Effectiveness of a 12-Week Combination Therapy of TMC647055 and TMC435 With and Without GSK23336805 With a Pharmacokinetic Enhancer With and Without Ribavirin in Patients Infected With Chronic Genotype 1 Hepatitis C Virus
The purpose of this study is to explore the efficacy and safety of TMC647055, TMC435, and low-dose ritonavir, administered together with and without ribavirin and of TMC647055, TMC435, low-dose ritonavir administered together…
- Trial name
- NCT01724086
- Testing
- TMC647055, TMC435, Ritonavir
- Where
- 10 sites in Belgium, Germany
- Volunteers
- 90 people
- Sponsor
- Janssen R&D Ireland
Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted, Hepatitis B, Chronic
Laboratory Profile of Hepatitis B and C in Users of a Reference Service
Chronic hepatitis by the B virus (HBV) and/or by the C virus (HCV) is a major public-health problem since it presents a long phase of clinical latency which makes its early diagnosis difficult and results in the development of a…
- Trial name
- NCT00512941
- Where
- 2 sites in Brazil
- Volunteers
- 531 people
- Sponsor
- UPECLIN HC FM Botucatu Unesp
Chronic Hepatitis C
Study of Nitazoxanide Combined With Peginterferon Compared to Peginterferon Monotherapy in the Treatment of Hepatitis C
The purpose of this study is to evaluate the safety and efficacy of nitazoxanide-peginterferon alfa-2b combination therapy compared to peginterferon monotherapy in patients that are treatment naive or pre-treated for 24 weeks…
- Trial name
- NCT00418054
- Testing
- Nitazoxanide plus peginterferon alfa-2b, Peginterferon alfa-2b
- Where
- 2 sites in Egypt
- Volunteers
- 40 people
- Sponsor
- Romark Laboratories L.C.
Chronic Hepatitis C Virus (HCV) Infection
A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Renally Impaired Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection
The purpose of this study is to assess the efficacy and safety of 12 weeks of treatment with the ABT-493/ABT-530 combination regimen in adults with chronic HCV genotype 1 - 6 infection and chronic severe renal impairment.
- Trial name
- EXPEDITION-4 (NCT02651194)
- Testing
- ABT-493/ABT-530
- Volunteers
- 104 people
- Sponsor
- AbbVie
Hepatitis C
Efficacy and Safety of Grazoprevir (MK-5172), Elbasvir (MK-8742), and Sofosbuvir for Chronic Infection With Hepatitis C Virus Genotypes 1 and 3 (MK-5172-074)
This is a study of grazoprevir (MK-5172) + elbasvir (MK-8742) and sofosbuvir (SOF) in treatment-naive participants with chronic hepatitis C (HCV) genotype (GT) 1 or GT3.
- Trial name
- NCT02133131
- Testing
- Grazoprevir/Elbasvir FDC, Sofosbuvir
- Volunteers
- 143 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Hepatitis C
Pegylated Interferon and Ribavirin in Hepatitis C Patients on Opioid Pharmacotherapy
The purpose of this study is to see if treatment of chronic hepatitis C in people who are on opiate replacement therapy such as methadone or buprenorphine (including patient who still inject drugs) is safe and effective.
- Trial name
- NCT01120795
- Testing
- Pegylated interferon and ribavirin
- Where
- 4 sites in Australia
- Volunteers
- 55 people
- Sponsor
- Melbourne Health
Hepatitis C, Chronic, DIABETES MELLITUS Type 2
The Role Of Nitazoxanide, Interferon Alfa And Ribavirin In Treatment Of Hepatitis C Infected Type 2 Diabetic Patients
The purpose of this study is to investigate if nitazoxanide used in combination with interferon alfa and ribavirin is effective in treating Hepatitis c infected type 2 Diabetic patients by improving their sustained viral response…
- Trial name
- HEP-C-FM (NCT01770483)
- Testing
- nitazoxanide, conventional interferon alfa, Ribavirin
- Where
- Pakistan
- Volunteers
- 66 people
- Sponsor
- Services Institute of Medical Sciences, Pakistan
Hepatitis C
Ribavirin Pre-treatment Followed by Combined Standard Therapy in Hepatitis C Virus (HCV) Recipients
The results of antiviral therapy in patients with recurrent hepatitis C after liver transplantation are lower than standard. Ribavirin has immune-modulating effects and seems to be crucial to optimize viral treatment.
- Trial name
- RBV (NCT00993122)
- Testing
- ribavirin pre-treatment
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- University of Roma La Sapienza
Acute Hepatitis C, HIV
To Assess Neuroinflammation and Neurocognitive Function in Patients With Acute Hepatitis C and Chronic HIV Co-Infection
This study plans to evaluate what happens to the brain in patients with HIV and early hepatitis C. The investigators will be comparing 3 groups of individuals: Group 1: Individuals with HIV infection and acute (early) hepatitis C…
- Conditions
- Acute Hepatitis C, HIV, HIV Infections
- Trial name
- NCT00959166
- Testing
- PET scan
- Where
- United Kingdom
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Hepatitis C, HIV
Drug Interaction Study With Ribavirin and Abacavir in Male Subjects With Hepatitis C Who Have Failed Ribavirin Treatment
This research is being done to find out whether abacavir (Ziagen®) lowers the levels of ribavirin (Ribapak®) in the body of persons taking these two drugs.
- Trial name
- NCT01052701
- Testing
- Ribavirin, Ribavirin plus Abacavir (ABC)
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Johns Hopkins University
Hepatitis C, Hepatitis B
Australian Hepatitis and Risk Survey in Prisons
The Australian Hepatitis and risk survey in prisons (AusHep) is a national prison-based blood-borne virus (BBV) surveillance study.
- Conditions
- Hepatitis C, Hepatitis B, HIV Infections
- Trial name
- AusHep (NCT05839522)
- Testing
- Point-of-care hepatitis C antibody test, Point-of-care hepatitis C RNA test, Point-of-care hepatitis B surface antibody test
- Where
- 24 sites in Australia
- Volunteers
- 2,400 people, healthy volunteers welcome
- Sponsor
- Kirby Institute
Hepatitis C, Chronic, Fibrosis
Efficacy of Prazosin Versus Placebo Associated With Peg-interferon Alpha 2b and Ribavirin in Chronic Hepatitis C With Genotype 1 or 4 and Severe Fibrosis
Viral hepatitis C prognosis is related to the presence of a fibrosis and to the risk of developing cirrhosis or hepatic cancer. The study will evaluate the efficacy of prazosin to make hepatic fibrosis regress, in patients with…
- Trial name
- PRAZOR (NCT00148837)
- Testing
- Peg-interferon alpha 2b + Ribavirin(drug), Prazosin (drug)
- Where
- France
- Volunteers
- 112 people
- Sponsor
- French National Agency for Research on AIDS and Viral Hepatitis
Heart Failure
Transplant of Redeemed Organs by Judicious Administration of New Direct-Acting Antivirals for Hepatitis-C Heart Recipients
This phase II, multi-center, open-label study will evaluate the safety and efficacy of utilizing HCV-positive donors for heart transplant in HCV-negative recipients treated with sofosbuvir 400 mg / velpatasvir 100 mg (Epclusa®).
- Trial name
- TROJAN-C (NCT03383419)
- Testing
- Epclusa
- Where
- 3 sites in United States
- Volunteers
- 15 people
- Sponsor
- Baylor Research Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.